Cargando…
Developing a genetic signature to predict drug response in ovarian cancer
There is a lack of personalized treatment options for women with recurrent platinum-resistant ovarian cancer. Outside of bevacizumab and a group of poly ADP-ribose polymerase inhibitors, few options are available to women that relapse. We propose that efficacious drug combinations can be determined...
Autores principales: | Hyter, Stephen, Hirst, Jeff, Pathak, Harsh, Pessetto, Ziyan Y., Koestler, Devin C., Raghavan, Rama, Pei, Dong, Godwin, Andrew K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871081/ https://www.ncbi.nlm.nih.gov/pubmed/29599910 http://dx.doi.org/10.18632/oncotarget.23663 |
Ejemplares similares
-
Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer
por: Braun, Mitchell W, et al.
Publicado: (2020) -
Drug discovery using clinical outcome-based Connectivity Mapping: application to ovarian cancer
por: Raghavan, Rama, et al.
Publicado: (2016) -
Correction: Epimorphin-Induced MET Sensitizes Ovarian Cancer Cells to Platinum
por: Yew, Kok-Hooi, et al.
Publicado: (2013) -
Aurora A kinase regulates non-homologous end-joining and poly(ADP-ribose) polymerase function in ovarian carcinoma cells
por: Do, Thuy-Vy, et al.
Publicado: (2017) -
In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma
por: Pessetto, Ziyan Y., et al.
Publicado: (2016)